Chemotherapy backbone and outcomes of immune checkpoint inhibitor combinations across solid tumors: a pan-tumor network meta-analysis.
Luisana Sisca, Mariam Grazia Polito, Alessio Cortellini et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis examined phase II–III randomised trials comparing first-line immune checkpoint inhibitor (ICI) plus chemotherapy with chemotherapy alone across solid tumours, assessing outcomes by chemotherapy backbone. Across 39 trials and over 30 000 patients, chemo-immunotherapy improved progression-free survival (HR 0.69, 95% CI 0.66-0.72) and overall survival (HR 0.78, 95% CI 0.76-0.81). Relative survival benefit varied across backbones, with platinum-pemetrexed showing the greatest reported benefit (HR 0.66). The authors caution that these cross-tumour differences are hypothesis-generating, not evidence that one backbone is superior.
Key findings
- Chemo-immunotherapy improved progression-free survival versus chemotherapy alone (HR 0.69, 95% CI 0.66-0.72).
- Overall survival also improved with chemo-immunotherapy (HR 0.78, 95% CI 0.76-0.81).
- Reported relative survival benefit was greatest with platinum-pemetrexed (HR 0.66), followed by platinum-taxane and fluoropyrimidine-platinum regimens (HR 0.78); platinum-gemcitabine showed lower benefit (HR 0.83).
- All ICI-chemotherapy combinations increased grade ≥3 adverse events.
Why it matters
The analysis highlights that outcomes reported for chemo-immunotherapy may differ across chemotherapy backbones, while also showing the difficulty of separating backbone effects from tumour-specific biology and standards of care. This distinction matters when interpreting pooled evidence: apparent differences across tumour types should not be treated as proof that one regimen is generally more effective.
What to keep in mind
Backbones were closely linked to tumour-specific standards of care and were not randomly distributed across tumour types, limiting cross-tumour comparisons. The authors describe the findings as hypothesis-generating and call for prospective validation within individual tumour types.